OVATION 2 Phase 1/2 trial

February 25, 2021August 24, 2022

FDA Grants Fast Track Status to Celsion’s GEN-1 for Advanced Cancer

News

Celsion‘s immunotherapy candidate, GEN-1, has received fast track designation from the U.S. Food and Drug Administration (FDA) for advanced ovarian cancer. This designation helps speed the approval of potential medicines ... Read more

August 28, 2019

Expert Discusses Celsion’s Ovarian Cancer Immunotherapy GEN-1; Phase 1/2 Trial Still Enrolling

News

The ovarian cancer immunotherapy candidate GEN-1, which is being tested in a Phase 1/2 clinical trial in newly diagnosed patients with advanced disease, was the focus of a recent call with ... Read more